Obicetrapib / Ezetimib (1) – Evlarco®

Primary hypercholesterolaemia or mixed dyslipidaemia

Characteristics

Start date 15.11.2026
Resolution 05.05.2027 – active procedure
INN Obicetrapib/Ezetimib
Brand name Evlarco®
Pharm. company Berlin-Chemie AG/Menarini Group
G-BA Procedure ID D-1393
Therapeutic area Metabolic diseases
Reason for procedure Initial assessment

Associated procedures

Obicetrapib / Ezetimib (1) Evlarco® Berlin-Chemie AG/Menarini Group Metabolic diseases Primary hypercholesterolaemia or mixed dyslipidaemia n.d. active procedure


<< List of all resolutions